Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Posted by on May 28th, 2026

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) have been given an average recommendation of “Moderate Buy” by the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have covered the stock in the last year is $17.1667.

A number of analysts recently issued reports on KPTI shares. Rodman & Renshaw raised Karyopharm Therapeutics to a “strong-buy” rating in a research report on Tuesday, March 10th. Robert W. Baird lowered their target price on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 25th. Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 target price (up from $8.00) on shares of Karyopharm Therapeutics in a research report on Monday, April 27th. HC Wainwright lifted their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Finally, Cantor Fitzgerald started coverage on Karyopharm Therapeutics in a research report on Thursday, February 5th. They issued an “overweight” rating on the stock.

Read Our Latest Research Report on KPTI

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Commodore Capital LP bought a new position in Karyopharm Therapeutics during the first quarter worth about $10,862,000. T. Rowe Price Investment Management Inc. grew its holdings in Karyopharm Therapeutics by 112.8% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,491,409 shares of the company’s stock worth $10,977,000 after purchasing an additional 790,417 shares during the period. Ikarian Capital LLC grew its holdings in Karyopharm Therapeutics by 1,897.9% during the fourth quarter. Ikarian Capital LLC now owns 544,554 shares of the company’s stock worth $4,008,000 after purchasing an additional 517,297 shares during the period. Geode Capital Management LLC grew its holdings in Karyopharm Therapeutics by 101.2% during the fourth quarter. Geode Capital Management LLC now owns 187,734 shares of the company’s stock worth $1,382,000 after purchasing an additional 94,445 shares during the period. Finally, Bank of America Corp DE grew its holdings in Karyopharm Therapeutics by 26.8% during the second quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after purchasing an additional 35,626 shares during the period. Institutional investors and hedge funds own 66.44% of the company’s stock.

Karyopharm Therapeutics Price Performance

KPTI opened at $8.98 on Friday. The business’s 50-day moving average price is $7.83 and its two-hundred day moving average price is $7.39. Karyopharm Therapeutics has a 1 year low of $3.65 and a 1 year high of $10.99. The company has a market capitalization of $203.49 million, a price-to-earnings ratio of -0.60 and a beta of 0.80.

Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.45) by $0.21. The firm had revenue of $35.07 million during the quarter, compared to analyst estimates of $31.40 million. Sell-side analysts anticipate that Karyopharm Therapeutics will post -3.52 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

(Get Free Report)

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.

Featured Stories

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.